[go: up one dir, main page]

PE20200484A1 - Tratamiento para el asma con anticuerpo anti-tslp - Google Patents

Tratamiento para el asma con anticuerpo anti-tslp

Info

Publication number
PE20200484A1
PE20200484A1 PE2019002026A PE2019002026A PE20200484A1 PE 20200484 A1 PE20200484 A1 PE 20200484A1 PE 2019002026 A PE2019002026 A PE 2019002026A PE 2019002026 A PE2019002026 A PE 2019002026A PE 20200484 A1 PE20200484 A1 PE 20200484A1
Authority
PE
Peru
Prior art keywords
asthma
treatment
tslp antibody
tslp
antibody
Prior art date
Application number
PE2019002026A
Other languages
English (en)
Inventor
Jane R Parnes
Janet Griffiths
Original Assignee
Amgen Inc
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Medimmune Llc filed Critical Amgen Inc
Publication of PE20200484A1 publication Critical patent/PE20200484A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripcion se refiere, en general, a metodos para tratar el asma, que incluyen asma grave y asma eosinofilico bajo, mediante el uso de un anticuerpo especifico para la linfopoyetina estromal timica (TSLP)
PE2019002026A 2017-04-12 2018-04-12 Tratamiento para el asma con anticuerpo anti-tslp PE20200484A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US201762553477P 2017-09-01 2017-09-01
US201762553575P 2017-09-01 2017-09-01
PCT/US2018/027271 WO2018191479A1 (en) 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody

Publications (1)

Publication Number Publication Date
PE20200484A1 true PE20200484A1 (es) 2020-03-03

Family

ID=62092313

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002026A PE20200484A1 (es) 2017-04-12 2018-04-12 Tratamiento para el asma con anticuerpo anti-tslp

Country Status (21)

Country Link
US (3) US10828365B2 (es)
EP (1) EP3609917A1 (es)
JP (4) JP7330896B2 (es)
KR (2) KR20240070727A (es)
CN (1) CN110573525A (es)
AU (2) AU2018253118B2 (es)
BR (1) BR112019021482A2 (es)
CA (1) CA3059364A1 (es)
CL (1) CL2019002897A1 (es)
CO (1) CO2019011462A2 (es)
IL (1) IL269791B (es)
JO (1) JOP20190243A1 (es)
MX (1) MX2019012158A (es)
MY (1) MY207509A (es)
PE (1) PE20200484A1 (es)
PH (1) PH12019502331A1 (es)
SG (1) SG11201909322VA (es)
TN (1) TN2019000289A1 (es)
TW (2) TW202523688A (es)
UY (1) UY37676A (es)
WO (1) WO2018191479A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180042433A (ko) * 2015-09-09 2018-04-25 노파르티스 아게 흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
MY208416A (en) 2019-06-04 2025-05-08 Shanghai hengrui pharmaceutical co ltd Antibody capable of binding to thymic stromal lymphopoietin and use thereof
KR20220033504A (ko) * 2019-07-11 2022-03-16 타보텍 바이오테라퓨틱스 (홍콩) 리미티드 흉선 기질 림프포이에틴(tslp)-수용체 신호전달을 방해하는 제제
US12479912B2 (en) 2019-09-04 2025-11-25 Biosion Inc. Monoclonal antibodies which bind thymic stromal lymphopoietin (TSLP), encoding polynucleotides thereof and methods of use thereof to treat diseases
CA3154999A1 (en) * 2019-10-28 2021-05-06 Catherine Eugenie Chaillan Huntington Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
CN114887053A (zh) * 2019-11-29 2022-08-12 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
EP4047019A4 (en) * 2019-12-13 2023-11-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ANTI-TSLP ANTIBODIES AND USES THEREOF
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CR20220457A (es) * 2020-02-13 2023-01-09 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
US20230073888A1 (en) * 2020-02-13 2023-03-09 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
AR121368A1 (es) * 2020-02-18 2022-06-01 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
CN119499366A (zh) * 2021-03-03 2025-02-25 正大天晴药业集团股份有限公司 含抗tslp抗体的药物组合物
IL307651A (en) * 2021-04-19 2023-12-01 Medimmune Ltd An anti-tslp fab with improved stability
JP2024517418A (ja) 2021-04-23 2024-04-22 アムジェン インコーポレイテッド 抗ｔｓｌｐ抗体組成物及びその使用
IL307439A (en) 2021-04-23 2023-12-01 Amgen Inc Different anti-TSLP antibodies
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗ｔｓｌｐ抗體組成物及其用途
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
WO2025049343A1 (en) * 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-tslp antibody constructs and uses thereof
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
MY162511A (en) 2009-11-04 2017-06-15 Merck Sharp & Dohme Engineered anti-tslp antibody
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
CA2924873A1 (en) * 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
CA2955086A1 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
RU2017134274A (ru) * 2015-03-11 2019-04-03 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Связывающие tslp белки
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp

Also Published As

Publication number Publication date
KR20190140956A (ko) 2019-12-20
CL2019002897A1 (es) 2020-03-06
US20180296669A1 (en) 2018-10-18
JOP20190243A1 (ar) 2019-10-13
JP2025170430A (ja) 2025-11-18
US20210052726A1 (en) 2021-02-25
MY207509A (en) 2025-02-28
CN110573525A (zh) 2019-12-13
TWI856945B (zh) 2024-10-01
US20250032608A1 (en) 2025-01-30
PH12019502331A1 (en) 2020-09-28
AU2018253118A1 (en) 2019-10-24
KR20240070727A (ko) 2024-05-21
JP2020516647A (ja) 2020-06-11
MX2019012158A (es) 2019-12-16
UY37676A (es) 2018-10-31
KR102666879B1 (ko) 2024-05-23
IL269791A (en) 2019-11-28
TW201838652A (zh) 2018-11-01
JP2024150751A (ja) 2024-10-23
TN2019000289A1 (en) 2021-05-07
CO2019011462A2 (es) 2019-10-31
AU2018253118B2 (en) 2025-04-10
AU2025204735A1 (en) 2025-07-17
CA3059364A1 (en) 2018-10-18
JP2023099233A (ja) 2023-07-11
US10828365B2 (en) 2020-11-10
IL269791B (en) 2022-07-01
JP7330896B2 (ja) 2023-08-22
WO2018191479A1 (en) 2018-10-18
EP3609917A1 (en) 2020-02-19
SG11201909322VA (en) 2019-11-28
TW202523688A (zh) 2025-06-16
BR112019021482A2 (pt) 2020-05-12

Similar Documents

Publication Publication Date Title
PE20200484A1 (es) Tratamiento para el asma con anticuerpo anti-tslp
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
IL257599A (en) Antibodies binding thymus thymus lymphopoietin (tslp) and methods of using the antibodies
CO2017000300A2 (es) Moléculas con especificidad para cd45 y cd79
MX2018016078A (es) Composiciones que comprenden cepas bacterianas.
MX2020006689A (es) Composiciones de vcar y metodos de uso.
MX2017000116A (es) Moleculas basadas en il-15 y metodos para su uso.
MX381718B (es) Agentes biologicos y su uso en plantas.
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
BR112018012839A2 (pt) composições endofíticas e métodos para melhoramento de traços de plantas em plantas de importância agronômica
BR112017008710A8 (pt) Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
BR112017014230A2 (pt) endófitos de semente através de cultivares e espécies, composições associadas e métodos de uso dos mesmos
MX2016013963A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
MX379312B (es) Anticuerpos especificos para fcrn.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
CO2022005391A2 (es) Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
CL2019002641A1 (es) Composiciones y métodos que involucran moléculas probióticas.
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
CL2019002323A1 (es) Anticuerpo dirigido a il-13ra2 y su uso.
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
CO2023015915A2 (es) Anticuerpos anti-ccr8